Diabetes Mellitus and the Prostate: The Odd Pairing

Area of Science:

• Urology
• Endocrinology
• Oncology

Background:

• Metabolic diseases, particularly type 2 diabetes mellitus (T2DM), significantly impact prostate health.
• Existing literature presents conflicting evidence regarding the relationship between T2DM and prostate diseases like prostate cancer (PCa) and benign prostatic hyperplasia (BPH).

Purpose of the Study:

• To conduct a comprehensive literature review on the associations between T2DM, anti-diabetic agents, and the development or progression of PCa and BPH.

Main Methods:

• Systematic review of existing scientific literature.
• Analysis of studies investigating T2DM's influence on PCa and BPH.
• Evaluation of the role of anti-diabetic medications in these conditions.

Main Results:

• T2DM may have a protective effect against PCa due to factors like patient phenotype, genomics, and effects on testosterone and prostatic vasculature, though this is debated.
• T2DM can exacerbate BPH symptoms and complicate treatment, with T2DM, obesity, and metabolic syndrome increasing BPH risk.
• Metformin shows promise in inhibiting PCa cell growth, with ongoing research into its anti-cancer properties.

Conclusions:

• A significant relationship exists between T2DM and prostate diseases (PCa and BPH).
• Optimal glycemic control is crucial for managing BPH symptoms in diabetic patients.
• Further research and close clinical monitoring are essential for understanding and managing these complex interactions.